Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.41 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28901520 | 1.00 | TXNRD1 (0.47) | TXNRD1GPR119PIK3CDMETPRKCQ | |
| SCHEMBL28469711 | 1.00 | TXNRD1 (0.47) | TXNRD1GPR119PIK3CDMETPRKCQ | |
| SCHEMBL28480884 | 0.94 | MET (0.42) | TXNRD1GPR119PIK3CDMETPRKCQ | |
| SCHEMBL28469727 | 0.94 | TXNRD1 (0.51) | TXNRD1GPR119METNAMPTPOLB | |
| SCHEMBL20471639 | 0.84 | TXNRD1 (0.47) | TXNRD1PAX8ALDH1A1LMNAMAPT | |
| SCHEMBL21247456 | 0.84 | TXNRD1 (0.47) | TXNRD1PAX8ALDH1A1LMNAMAPT | |
| SCHEMBL20471643 | 0.84 | TXNRD1 (0.47) | TXNRD1PAX8ALDH1A1LMNAMAPT | |
| SCHEMBL15917743 | 0.84 | GPR119 (0.47) | GPR119PIK3CDNAMPTPOLBUSP30 | |
| SCHEMBL20471646 | 0.79 | SMN1; SMN2 (0.49) | TXNRD1PAX8ALDH1A1LMNAMAPT | |
| SCHEMBL14335034 | 0.78 | PIK3CD (0.52) | GPR119PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168069-B2 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-09 | — | — | US | claimed |
| US-11168069-B2 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer | OBLIQUE THERAPEUTICS AB (SE) | 2021-11-09 | — | — | US | disclosed |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2021-02-11 | — | — | US | disclosed |
| EP-3752151-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Cinda Pharma AB (SE) | 2020-12-23 | — | — | EP | disclosed |
| CN-111867587-A | Thioredoxin reductase inhibitors for the treatment of cancer | 信达制药公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019155086-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CINDA PHARMA AB (SE) | 2019-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168069-B2 | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer | TP53, CCNI, IDH1 | TXNRD1 279/4885GPR119 3139/4885PIK3CD 3557/4885 |
| US-20210038577-A1 | THIOREDOXIN REDUCTASE INHIBITORS FOR USE IN THE TREATMENT OF CANCER | TXNRD3, TXNRD1, TXNRD2 | TXNRD1 2/4885GPR119 2928/4885PIK3CD 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.